WO2002067957A8 - Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier - Google Patents

Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier

Info

Publication number
WO2002067957A8
WO2002067957A8 PCT/US2002/006719 US0206719W WO02067957A8 WO 2002067957 A8 WO2002067957 A8 WO 2002067957A8 US 0206719 W US0206719 W US 0206719W WO 02067957 A8 WO02067957 A8 WO 02067957A8
Authority
WO
WIPO (PCT)
Prior art keywords
blood cells
red blood
hemoglobin
oxygen carrier
based oxygen
Prior art date
Application number
PCT/US2002/006719
Other languages
French (fr)
Other versions
WO2002067957A1 (en
Inventor
Maria S Gawryl
Robert A Houtchens
William R Light
Original Assignee
Biopure Corp
Maria S Gawryl
Robert A Houtchens
William R Light
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopure Corp, Maria S Gawryl, Robert A Houtchens, William R Light filed Critical Biopure Corp
Priority to NZ527882A priority Critical patent/NZ527882A/en
Priority to AU2002250229A priority patent/AU2002250229B2/en
Priority to CA2439123A priority patent/CA2439123C/en
Priority to JP2002567323A priority patent/JP2004535368A/en
Priority to EP02719129A priority patent/EP1443947A1/en
Publication of WO2002067957A1 publication Critical patent/WO2002067957A1/en
Publication of WO2002067957A8 publication Critical patent/WO2002067957A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Abstract

Red blood cells are purified by defibrinating whole blood and then filtering the defibrinated whole blood, whereby at least a portion of a plasma component is separated from the red blood cells to form a suspension of red blood cells, thereby purifying the red blood cells. Whole blood is defibrinated by, for example, using a chemical coagulating agent or mechanical agitation. Separation of the plasma component from red blood cells can be completed by, for example, diafiltration. The suspension of red blood cells can then be employed to produce a hemoglobin-based oxygen carrier.
PCT/US2002/006719 2001-02-28 2002-02-28 Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier WO2002067957A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
NZ527882A NZ527882A (en) 2001-02-28 2002-02-28 Manufacture of a hemoglobin-based oxygen carrier
AU2002250229A AU2002250229B2 (en) 2001-02-28 2002-02-28 Manufacture of a hemoglobin-based oxygen carrier
CA2439123A CA2439123C (en) 2001-02-28 2002-02-28 Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier
JP2002567323A JP2004535368A (en) 2001-02-28 2002-02-28 Production of hemoglobin-based oxygen carriers
EP02719129A EP1443947A1 (en) 2001-02-28 2002-02-28 Use of defibrinated blood for the manufacture of a hemoglobin-based oxygen carrier

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/795,821 US6518010B2 (en) 2001-02-28 2001-02-28 Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier
US09/795,821 2001-02-28

Publications (2)

Publication Number Publication Date
WO2002067957A1 WO2002067957A1 (en) 2002-09-06
WO2002067957A8 true WO2002067957A8 (en) 2004-07-29

Family

ID=25166541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/006719 WO2002067957A1 (en) 2001-02-28 2002-02-28 Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier

Country Status (8)

Country Link
US (3) US6518010B2 (en)
EP (1) EP1443947A1 (en)
JP (1) JP2004535368A (en)
CN (1) CN1269955C (en)
AU (1) AU2002250229B2 (en)
CA (2) CA2756609C (en)
NZ (1) NZ527882A (en)
WO (1) WO2002067957A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518010B2 (en) * 2001-02-28 2003-02-11 Biopure Corporation Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier
CA2476177C (en) * 2002-02-28 2011-06-14 Biopure Corporation Purification of red blood cells by separation and diafiltration
US7001715B2 (en) * 2002-02-28 2006-02-21 Biopure Corporation Purification of red blood cells by separation and diafiltration
CN1954883B (en) * 2005-10-28 2011-06-15 陕西北美基因股份有限公司 Method for stabilizing hemoglobin oxygen carrier sample
CN101750244B (en) * 2008-10-13 2014-03-12 艾博生物医药(杭州)有限公司 Method for separating red cells from blood sample and application
CN103760333B (en) * 2009-10-13 2016-03-16 艾博生物医药(杭州)有限公司 Erythrocytic method and utilization in a kind of separating blood sample
US11864553B2 (en) * 2009-10-23 2024-01-09 Fenwal, Inc. Methods and systems for providing red blood cell products with reduced plasma
US7989593B1 (en) 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
WO2013043433A2 (en) * 2011-09-22 2013-03-28 Fenwal, Inc. Disposable fluid circuits and methods for cell washing
US9744498B2 (en) 2011-03-11 2017-08-29 Fenwal, Inc. Disposable fluid circuits and methods for cell washing with on-line dilution of cell feed
US8084581B1 (en) 2011-04-29 2011-12-27 Bing Lou Wong Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
EP2550973B1 (en) * 2011-07-23 2013-08-28 SastoMed GmbH Wound spray
US20130052232A1 (en) 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
CN103861161B (en) * 2012-12-18 2016-06-08 苏州排头兵药业科技有限公司 The preparation method of Washed Red Blood Cells device and Washed Red Blood Cells
AU2018304174A1 (en) 2017-07-18 2020-02-06 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making
DE102018211281A1 (en) * 2018-07-09 2020-01-09 Robert Bosch Gmbh Microfluidic device and method for diluting and separating particles of a sample
WO2021034416A2 (en) 2019-07-02 2021-02-25 Hbo2 Therapeutics, Llc Hemoglobin substitute mixtures including reconstituted plasma and platelets and their manufacture and use
AU2021297879A1 (en) * 2020-06-23 2023-02-09 VirTech Bio, Inc. Compositions and methods for treating hemorrhagic shock
CN113769189B (en) * 2021-09-02 2023-10-27 南通大学 Non-isolated insulin controlled-release drug entrapment equipment and entrapment method
CN117100905A (en) * 2023-10-25 2023-11-24 润方（北京）生物医药研究院有限公司 Dressing for promoting wound healing

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3973001A (en) * 1954-04-27 1976-08-03 Solco Basel Ag Tissue cell stimulating blood extracts
GB824375A (en) 1955-12-13 1959-11-25 Solco Basel Ag Respiration-stimulant substances from blood
DE2248475C3 (en) 1972-10-03 1978-09-28 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Process for obtaining hepatic-safe, storage-stable and infusable hemoglobin solutions
SU455738A1 (en) 1972-12-25 1975-01-05 Институт Экологии Растений И Животных Уральского Научного Центра Ан Ссср The method of obtaining dry erythrocyte diagnosticum for the detection of species-specific antiglobulins
US4001200A (en) 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4001401A (en) 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4061736A (en) 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4053590A (en) 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US3991181A (en) 1975-06-18 1976-11-09 Warner-Lambert Company Injectable stroma free hemoglobin solution and its method of manufacture
US4401652A (en) 1980-12-31 1983-08-30 Allied Corporation Process for the preparation of stroma-free hemoglobin solutions
DE3130770C2 (en) 1981-08-04 1986-06-19 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Process for obtaining hepatitis-safe, sterile, pyrogen-free and stroma-free hemoglobin solutions
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US5194590A (en) 1986-06-20 1993-03-16 Northfield Laboratories, Inc. Acellular red blood cell substitute
US4826811A (en) 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
US5753616A (en) 1986-11-10 1998-05-19 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5854209A (en) 1995-03-23 1998-12-29 Biopure Corporation Method for oxygenating tissue having reduced red blood cell flow
US5084558A (en) 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
WO1988003408A1 (en) 1986-11-10 1988-05-19 Biopure Corporation Extra pure semi-synthetic blood substitute
GB8710598D0 (en) 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
US5189146A (en) 1987-05-05 1993-02-23 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Pasteurizable, freeze-driable hemoglobin-based blood substitute
AT392003B (en) 1988-01-13 1991-01-10 Broschek G Chem Prod Gebro METHOD FOR PRODUCING A PARTICULARLY FOR Wounds Healing Or For Treatment In Geriatrics, Active Ingredients From Mammalian Blood By PAPAINE HYDROLYSIS AND A PREPARATION CONTAINING SUCH AN ACTIVE SUBSTANCE
US4861867A (en) 1988-02-03 1989-08-29 Baxter International, Inc. Purified hemoglobin solutions and method for making same
WO1989012456A1 (en) 1988-06-15 1989-12-28 Baxter International Inc. Method of purifying cross-linked hemoglobin
US5045529A (en) 1989-03-27 1991-09-03 Bionostics, Inc. Tonometric fluid for blood gas and co-oximetry instruments
US5439882A (en) 1989-12-29 1995-08-08 Texas Tech University Health Sciences Center Blood substitute
US5547873A (en) 1994-02-22 1996-08-20 Genzyme Corporation Compositions for stabilizing proteins for long term dry storage and methods of making and using the compositions
US5296466A (en) 1992-02-19 1994-03-22 Board Of Regents, The University Of Texas System Inhibition of nitric oxide-mediated hypotension and septic shock with iron-containing hemoprotein
US5264555A (en) 1992-07-14 1993-11-23 Enzon, Inc. Process for hemoglobin extraction and purification
WO1994022482A1 (en) 1993-03-26 1994-10-13 Biorelease Technologies, Inc. Compositions including heme-containing proteins and methods relating thereto
US5545328A (en) 1993-09-21 1996-08-13 Hemosol Inc. Purification of hemoglobin by displacement chromatography
US5691452A (en) 1995-03-23 1997-11-25 Biopure Corporation Method for preserving a hemoglobin blood substitute
US6271351B1 (en) 1995-03-23 2001-08-07 Biopure Corporation Method for preserving a hemoglobin blood substitute
US5895810A (en) 1995-03-23 1999-04-20 Biopure Corporation Stable polymerized hemoglobin and use thereof
EP1093720B1 (en) 1995-03-23 2009-11-04 Biopure Corporation Stable polymerized hemoglobin blood-substitute
US5691453A (en) 1995-06-07 1997-11-25 Biopure Corporation Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC
US5808011A (en) 1996-07-01 1998-09-15 Biopure Corporation Method for chromatographic removal of prions
US6518010B2 (en) 2001-02-28 2003-02-11 Biopure Corporation Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier

Also Published As

Publication number Publication date
JP2004535368A (en) 2004-11-25
WO2002067957A1 (en) 2002-09-06
US20060084137A1 (en) 2006-04-20
US7553613B2 (en) 2009-06-30
US6518010B2 (en) 2003-02-11
CA2439123A1 (en) 2002-09-06
NZ527882A (en) 2006-03-31
AU2002250229B2 (en) 2004-11-25
US20020161197A1 (en) 2002-10-31
CN1499978A (en) 2004-05-26
CA2756609C (en) 2015-06-09
US20030113707A1 (en) 2003-06-19
CA2756609A1 (en) 2002-09-06
EP1443947A1 (en) 2004-08-11
US6986984B2 (en) 2006-01-17
CA2439123C (en) 2012-02-21
CN1269955C (en) 2006-08-16

Similar Documents

Publication Publication Date Title
WO2002067957A8 (en) Use of defibrinated blood for manufacture of a hemoglobin-based oxygen carrier
WO2005063971A3 (en) Definitive endoderm
WO2004024300A8 (en) Ultrafiltration membrane, device, bioartificial organ and methods
WO2000055621A8 (en) Blood leucocyte apheresis for treatment of disease
MY141778A (en) Process for the separation of olefins from paraffins using membranes
DE60203551D1 (en) Production of high purity oxygen by pressure swing adsorption
DE3886297T2 (en) Process for the production of high-purity oxygen gas from air.
AU1681288A (en) Improved process for recovering microbially produced IL-2
AU7007491A (en) Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
ATE512153T1 (en) SALT OF A SULFONIC ACID WITH CLOPIDOGREL AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL FORMULATIONS
DE60132094D1 (en) Process for the preparation of purified particles
WO2004026254A3 (en) Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
WO2002056826A3 (en) Method for producing purified hematinic iron-saccharidic complex and product produced
MXPA05011803A (en) Method for producing propylene oxide.
WO2001074159A3 (en) Systems and methods for collecting plasma that is free or virtually free of cellular blood species
WO2006084002A3 (en) Multi-stage sulfur removal system and process for an auxiliary fuel system
WO2003029136A3 (en) Purification of endohedral and other fullerenes by chemical methods
WO2004068109A3 (en) Autologous or homologous coagulant produced from anticoagulated whole blood
WO2005030040A3 (en) Hematopoietic stem cell identification and isolation
MY126838A (en) Purification of protein inclusion bodies by crossflow microfiltration.
WO2004066942A3 (en) Purification and uses of dendritic cells and monocytes
DE50103427D1 (en) METHOD FOR PRODUCING HIGH PURITY, GRANULAR SILICON
AU2002360928A1 (en) A method for manufacturing and fractionating gelling and non-gelling carrageenans from bi-component seaweed
WO2022159679A3 (en) Method for purifying recombinant viral particles
FI20011327A (en) Procedure for cleaning gasification gas

Legal Events

Date Code Title Description
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2439123

Country of ref document: CA

Ref document number: 2002567323

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002250229

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002719129

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 527882

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 028073584

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

WWP Wipo information: published in national office

Ref document number: 2002719129

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002250229

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 527882

Country of ref document: NZ